BioSpace News Archive

Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4

Novartis is committed to bringing BEOVU 6 mg to DME patients and will submit data from KESTREL and KITE to global health authorities in H1 2021

Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease

Analytical assessment demonstrates structural, physicochemical, and biological similarity between SB11 and Lucentis

GEM103 demonstrates anti-angiogenic activity in a mouse model of laser-induced choroidal neovascularization (CNV)

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, announced that clinical data related to REL-1017, the company’s lead product candidate, will be presented in two posters at the American Psychiatric Association Annual Meeting 2021, which is being held virtually between May 1 and May 3, 2021.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Oyster Point Pharma, Inc. announced the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting, being held on May 1-5.

Chiesi Global Rare Diseases announced that the U.S. Food & Drug Administration has approved FERRIPROX® for the treatment of transfusional iron overload due to sickle cell disease or other anemias in adult and pediatric patients 3 years of age and older.

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced new long-term data from the OPTIC clinical trial of ADVM-022 single intravitreal injection gene therapy in patients requiring frequent anti-VEGF injections for their neovascular or wet age-related macular degeneration.